Title:
ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/006804
Kind Code:
A1
Abstract:
Provided are an application of a compound represented by formula I as a ligand of an orphan nuclear receptor Nur77, and an application for preventing or treating a disease related to the orphan nuclear receptor Nur77.
More Like This:
Inventors:
ZHANG XIAOKUN (CN)
LIN XIANGZHI (CN)
SU YING (CN)
ZENG ZHIPING (CN)
HU MENGJIE (CN)
LUO QIANG (CN)
ZHU YI (CN)
GULIMIRAN ALITONGBIEKE (CN)
LIN XIANGZHI (CN)
SU YING (CN)
ZENG ZHIPING (CN)
HU MENGJIE (CN)
LUO QIANG (CN)
ZHU YI (CN)
GULIMIRAN ALITONGBIEKE (CN)
Application Number:
PCT/CN2017/091726
Publication Date:
January 11, 2018
Filing Date:
July 04, 2017
Export Citation:
Assignee:
UNIV XIAMEN (CN)
International Classes:
C07J63/00; A61K31/56; A61P35/00
Domestic Patent References:
| WO2015148802A1 | 2015-10-01 |
Foreign References:
| CN105985401A | 2016-10-05 | |||
| CN101351211A | 2009-01-21 |
Other References:
HU , MENGJIE ET AL.: "Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy", MOLECULAR CELL, vol. 66, no. 1, 6 April 2017 (2017-04-06), pages 141 - 153, XP029970893
KLAIC, L. ET AL.: "Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastro l", J. AM. CHEM. SOC., vol. 133, no. 49, 16 November 2011 (2011-11-16), pages 19634 - 19637, XP055192971
LU , ZHONGZHENG ET AL.: "Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-K B signaling and depleting Bcr-Abl", MOLECULAR CANCER, vol. 9, no. 112, 19 May 2010 (2010-05-19), pages 1 - 17, XP021077860
LEE, JINSUN ET AL.: "Anticancer Activity of Pristimerin in Epidermal Growth Factor Receptor 2-Positive SKBR3 Human Breast Cancer Cells", BIOL. PHARM. BULL., vol. 36, no. 2, 1 January 2013 (2013-01-01), pages 316 - 325, XP055588221, ISSN: 0918-6158, DOI: 10.1248/bpb.b12-00685
DING, HAIPENG ET AL.: "Research progress in pharmacologic molecular targets of celastrol", CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY, vol. 26, no. 4, 31 August 2012 (2012-08-31), pages 570 - 576, XP055588234, DOI: 10.3867/j.issn.1000-3002.2012.04.018
See also references of EP 3480207A4
KLAIC, L. ET AL.: "Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastro l", J. AM. CHEM. SOC., vol. 133, no. 49, 16 November 2011 (2011-11-16), pages 19634 - 19637, XP055192971
LU , ZHONGZHENG ET AL.: "Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-K B signaling and depleting Bcr-Abl", MOLECULAR CANCER, vol. 9, no. 112, 19 May 2010 (2010-05-19), pages 1 - 17, XP021077860
LEE, JINSUN ET AL.: "Anticancer Activity of Pristimerin in Epidermal Growth Factor Receptor 2-Positive SKBR3 Human Breast Cancer Cells", BIOL. PHARM. BULL., vol. 36, no. 2, 1 January 2013 (2013-01-01), pages 316 - 325, XP055588221, ISSN: 0918-6158, DOI: 10.1248/bpb.b12-00685
DING, HAIPENG ET AL.: "Research progress in pharmacologic molecular targets of celastrol", CHINESE JOURNAL OF PHARMACOLOGY AND TOXICOLOGY, vol. 26, no. 4, 31 August 2012 (2012-08-31), pages 570 - 576, XP055588234, DOI: 10.3867/j.issn.1000-3002.2012.04.018
See also references of EP 3480207A4
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: